Haloperidol versus haloperidol plus ondansetron for the prophylaxis of postoperative nausea and vomiting after ophthalmologic surgery

Pharmacology. 2009;83(4):205-10. doi: 10.1159/000196812. Epub 2009 Jan 28.

Abstract

Introduction: In this prospective, randomized, and double-blinded study we investigated the efficacy of haloperidol (10 microg/kg) and the combination of haloperidol (10 microg/kg) with ondansetron (0.1 mg/kg) for the prophylaxis of postoperative nausea and vomiting (PONV) after ophthalmologic surgery.

Methods: 60 patients (ASA status 1-3) with risk factors for PONV (female, non-smoker, motion sickness or PONV in history, opioids for postoperative analgesia) undergoing retinal or strabismus surgery were included into the study and randomised to the haloperidol group (H-Group) or the haloperidol-ondansetron group (H/O-Group). 20 min before the end of anaesthesia the study medication was given. Nausea, vomiting, pain scores, and adverse events were assessed postoperatively over 24 h.

Results: The incidence of PONV was lower for the H/O-Group (23 vs. 57% for the H-Group). Especially the incidence of vomiting was reduced for the H/O-Group (7 vs. 27% in the H-Group). No significant differences could be detected regarding adverse events.

Conclusion: The single use of haloperidol for the prophylaxis of PONV is doubtful. Better results were obtained with the combination therapy of haloperidol with ondansetron, especially for vomiting.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Haloperidol / administration & dosage*
  • Haloperidol / adverse effects
  • Haloperidol / therapeutic use*
  • Humans
  • Middle Aged
  • Ondansetron / administration & dosage*
  • Ondansetron / adverse effects
  • Ondansetron / therapeutic use*
  • Ophthalmologic Surgical Procedures / adverse effects*
  • Pain Measurement
  • Pain, Postoperative / drug therapy
  • Postoperative Nausea and Vomiting / prevention & control*
  • Risk Factors
  • Time Factors

Substances

  • Ondansetron
  • Haloperidol